Invesaro

Stocks Health care CDIX

OTC · Health care

Cardiff Lexington Corp (CDIX)

Cardiff Lexington Corp brought in $10.2M of revenue over the twelve months to June 30, 2026, up 0.3% from a year earlier. It posted a net loss of $9.4M. At June 30, 2026 it held $217.7K in cash against $22.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch CDIX in 60 seconds
Price
$0.42
0.00% on the day · September 25, 2026
52-week range $0.12 to $6.00
Market cap
$6.6M
Revenue (last 12 months)
$10.2M
+0.3% year on year
Net margin
-92.1%

What Cardiff Lexington Corp does

Cardiff Lexington Corp is registered with the SEC under industry code SIC 8011 (Services-Offices & Clinics of Doctors of Medicine). Its shares trade on OTC under the ticker CDIX.

Revenue and profit by year

Revenue
FY18: $2.2M $2.2M FY18FY19: $4.5M $4.5M FY19FY20: $3.5M $3.5M FY20FY21: $9.9M $9.9M FY21FY22: $10.7M $10.7M FY22FY23: $11.9M $11.9M FY23FY24: $8.3M $8.3M FY24FY25: $11.5M $11.5M FY25
Net income
FY18: -$6.3M -$6.3M FY18FY19: -$7.2M -$7.2M FY19FY20: -$2.8M -$2.8M FY20FY21: $666.3K $666.3K FY21FY22: -$5.4M -$5.4M FY22FY23: $3M $3M FY23FY24: -$3.3M -$3.3M FY24FY25: -$5.5M -$5.5M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$11.5M$1.1M-$5.5Mn/an/a
2024$8.3M-$193.5K-$3.3Mn/an/a
2023$11.9M$5.2M$3Mn/an/a
2022$10.7M$3.9M-$5.4Mn/a-$1.2M
2021$9.9M$1.7M$666.3K-$0.01-$853.5K
2020$3.5M-$1.8M-$2.8Mn/a-$903.4K

Full financial statements: income, balance sheet and cash flow

Next report expected around November 11, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 12, 2025. Not a date the company has announced. See the report calendar

Where CDIX ranks in Health care

Revenue$11.5M
#508 of 742 in Health care · Bottom 32%
Revenue growth+39.5%
#111 of 529 in Health care · Top 21%
Net margin-47.7%
#397 of 541 in Health care · Bottom 27%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out $50K in cash dividends.

Fiscal yearPer sharePaid outOf profit
2025n/a$50Kn/a
2024n/a$100Kn/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Cardiff Lexington Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 24, 2026
  2. September 4, 2026
  3. August 12, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue fell 23% to $2.2M versus the same quarter last year; diluted EPS -$0.18 versus -$0.24.
  4. June 23, 2026
  5. June 11, 2026
  6. June 11, 2026
  7. June 11, 2026
  8. May 13, 2026
    Quarterly report 10-Q · period to March 31, 2026Revenue fell 24% to $2.2M versus the same quarter last year; diluted EPS -$0.23 versus -$0.14.
  9. May 12, 2026
  10. April 30, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 15, 2026. Insider transactions on SEC

Insider trades

What the people running Cardiff Lexington Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
April 1, 2026 Johnson Gillard B. IIIDirector Received as pay 5,000 - - Form 4
April 1, 2026 Pennington Catherine B.Director Received as pay 5,000 - - Form 4
April 1, 2026 Staley Louis Jack Sr.Director Received as pay 5,000 - - Form 4
January 29, 2026 Cunningham Alex H.Chief Executive Officer, Director, 10% owner Other change 556,528 - - Form 4
January 13, 2026 Shafer Matthew TChief Financial Officer Received as pay 62,500 - - Form 4
November 19, 2025 Thompson DanielChairman of the Board, Director, 10% owner Exercised options 9,192,092 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CDIX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

6 insiders reported holding 15,725,959 shares in total, about $6.6M at the last price.

HolderSharesAs of
Thompson DanielChairman of the Board, Director, 10% owner 11,702,55736,128 held indirectly November 19, 2025
Cunningham Alex H.Chief Executive Officer, Director, 10% owner 3,914,230 January 29, 2026
Shafer Matthew TChief Financial Officer 74,168 January 13, 2026
Johnson Gillard B. IIIDirector 11,668 April 1, 2026
Staley Louis Jack Sr.Director 11,668 April 1, 2026
Pennington Catherine B.Director 11,668 April 1, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CDIX

What does Cardiff Lexington Corp do?

Cardiff Lexington Corp is registered with the SEC under industry code SIC 8011 (Services-Offices & Clinics of Doctors of Medicine). Its shares trade on OTC under the ticker CDIX.

Is Cardiff Lexington Corp profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $9.4M on revenue of $10.2M.

How much revenue does Cardiff Lexington Corp make?

Over the twelve months to June 30, 2026 Cardiff Lexington Corp reported revenue of $10.2M. That is 0.3% more than a year earlier.

When did Cardiff Lexington Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 24, 2026.

Similar companies

Compare CDIX with

Compare CDIX with any company

Follow CDIX

Get an email when Cardiff Lexington Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow CDIX: get an email when it files

Where the numbers come from

Financial figures are the values Cardiff Lexington Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.